1. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.
   Yuko Nakayama et al, 2020, Gastric Cancer CrossRef
2. Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer
   Aung Kyi Thar Min et al, 2020, Cancer Immunol Immunother CrossRef
3. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota
   Marine Fidelle et al, 2020, Front. Immunol. CrossRef
4. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses
   Guanglin Cui, 2021, Front. Oncol. CrossRef
5. PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells
   Tobias Gutting et al, 2021, OncoImmunology CrossRef
6. Analysis of multi-omics differences in left-side and right-side colon cancer.
   Yanyi Huang et al, 2021, PeerJ CrossRef
7. Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden
   Sofia Sagredou et al, 2021, Pharmaceutics CrossRef
8. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
   Elena Shklovskaya et al, 2021, IJMS CrossRef
9. Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
   Bin-Jin Hwang et al, 2022, J Immunother Cancer CrossRef
10. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Haizhou Wang et al, 2022, J Immunother Cancer CrossRef
11. Tumor microenvironment-aware, single-transcriptome prediction of microsatellite instability in colorectal cancer using meta-analysis
    Mi-Kyoung Seo et al, 2022, Sci Rep CrossRef
12. Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer
    Akinao Kaneta et al, 2022, Cancer Immunol Immunother CrossRef
13. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy
    Pasquale Sibilio et al, 2022, Biol Direct CrossRef
14. Identification of a Genomic Instability-Related Long Noncoding RNA Prognostic Model in Colorectal Cancer Based on Bioinformatic Analysis
    Yu Liang et al, 2022, Disease Markers CrossRef
15. CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
    Xiaofei Li et al, 2022, OncoImmunology CrossRef
16. Blood glutamate scavengers increase pro-apoptotic signaling and reduce metastatic melanoma growth in-vivo
    Yona Goldshmit et al, 2021, Sci Rep CrossRef
17. Single‐cell dissection reveals the role of DNA damage response patterns in tumor microenvironment components contributing to colorectal cancer progression and immunotherapy
    Xin Shen et al, 2023, Genes to Cells CrossRef
18. Interleukin-12: Structure, Function, and Its Impact in Colorectal Cancer
    Ziwei Zhu et al, 2024, Journal of Interferon & Cytokine Research CrossRef
19. Immunological tolerance in breast cancer: some reasons for development
    E. V. Kayukova et al, 2024, Usp. mol. onkol CrossRef